Form 4: CRISPR Therapeutics Director John Greene Granted 13,000 Stock Options

CRISPR Therapeutics AG Director John Greene was granted 13,000 stock options with an exercise price of $38.57, vesting over 12 months.

Summary

• John Greene, a Director of CRISPR Therapeutics AG (CRSP), was granted 13,000 stock options.
• The stock options have an exercise price of $38.57 per common share.
• The grant date for these options was June 5, 2025.
• The options are set to expire on June 5, 2035.
• Vesting will occur in 12 equal monthly installments, commencing on June 30, 2025.
• The final installment will vest on the earlier of the one-year anniversary of the grant date or the date of the 2026 Annual General Meeting of Shareholders.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed as a positive step for corporate governance, as it aligns the director's financial interests with the long-term performance of the company and its shareholders. This is a routine compensation disclosure.

Positives

• The grant of stock options to a director, John Greene, aligns his interests with those of the shareholders, potentially incentivizing long-term performance.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Future Outlook

The document details the vesting schedule for the granted stock options, indicating that the shares will vest over 12 equal monthly installments beginning June 30, 2025, with the final installment vesting by the earlier of the one-year anniversary of the grant or the 2026 Annual General Meeting of Shareholders.

Industry Context

This Form 4 filing is a standard disclosure of an insider transaction, specifically an equity grant to a director. It does not provide information on broader industry trends or competitive landscape, but rather details a specific compensation event within the company.

Related Party Transactions

• The grant of 13,000 stock options to John Greene, a Director of CRISPR Therapeutics AG, constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant of options to a director can align management incentives with shareholder value creation, potentially leading to better long-term performance.
• Director (John Greene): Receives equity-based compensation, providing a direct financial interest in the company's stock performance.

Next Steps

• Monthly vesting of the 13,000 stock options beginning June 30, 2025.
• Potential exercise of vested stock options by John Greene prior to the expiration date of June 5, 2035.

Key Dates

Keywords

CRISPR Therapeutics, CRSP, Stock Option, Director, Equity Grant, Insider Transaction, Form 4, John Greene